 |
47 Diseases |  |
1 Trial |
|
1 Trial |  |
197 News |  |
| «123 |
- | Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Trial completion, Trial primary completion date: Pharmacokinetic Study of ASP1517 With Kremezin (clinicaltrials.gov) - May 3, 2016
P1, N=34, Completed, Sponsor: Astellas Pharma Inc
Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2016
- Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Enrollment open: Pharmacokinetic Study of ASP1517 With Kremezin (clinicaltrials.gov) - Mar 27, 2016
P1, N=34, Recruiting, Sponsor: Astellas Pharma Inc
Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2016 Not yet recruiting --> Recruiting
- | Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
New P1 trial: Pharmacokinetic Study of ASP1517 With Kremezin (clinicaltrials.gov) - Feb 29, 2016
P1, N=34, Not yet recruiting, Sponsor: Astellas Pharma Inc
- || Kremezin (AST-120) / Mitsubishi Tanabe
New P3 trial: A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury (clinicaltrials.gov) - Feb 22, 2016
P3, N=206, Recruiting, Sponsor: National Taiwan University Hospital
- ||||| Kremezin (AST-120) / Mitsubishi Tanabe
New P4 trial: A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure (clinicaltrials.gov) - Feb 16, 2016
P4, N=152, Recruiting, Sponsor: Daewon Pharmaceutical Co., Ltd.
- ||||| Kremezin (AST-120) / Mitsubishi Tanabe
Enrollment change: Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas (clinicaltrials.gov) - May 26, 2014
P3, N=191, Completed, Sponsor: Ocera Therapeutics
Not yet recruiting --> Recruiting N=240 --> 191
- Kremezin (AST-120) / Mitsubishi Tanabe
Trial primary completion date: Effect of Replacement Volume of Haemodiafiltration and AST-120 on Toxins, Oxidative Stress and MicroInflammation (clinicaltrials.gov) - May 7, 2014
P4, N=30, Completed, Sponsor: Tungs
N=240 --> 191 Trial primary completion date: Mar 2013 --> Oct 2013
- Kremezin (AST-120) / Mitsubishi Tanabe
Trial completion date: Effect of Replacement Volume of Haemodiafiltration and AST-120 on Toxins, Oxidative Stress and MicroInflammation (clinicaltrials.gov) - May 7, 2014
P4, N=30, Completed, Sponsor: Tungs
Trial primary completion date: Mar 2013 --> Oct 2013 Trial completion date: Apr 2013 --> Oct 2013
- Kremezin (AST-120) / Mitsubishi Tanabe
Trial completion: Effect of Replacement Volume of Haemodiafiltration and AST-120 on Toxins, Oxidative Stress and MicroInflammation (clinicaltrials.gov) - May 7, 2014
P4, N=30, Completed, Sponsor: Tungs
Trial completion date: Apr 2013 --> Oct 2013 Active, not recruiting --> Completed
- |||| Kremezin (AST-120) / Mitsubishi Tanabe
Trial completion: K-STAR: Kremezin Study Against Renal Disease Progression in Korea (clinicaltrials.gov) - Mar 16, 2014
P4, N=578, Completed, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Kremezin (AST-120) / Mitsubishi Tanabe
Trial termination: Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis (clinicaltrials.gov) - May 20, 2013
P2, N=2, Terminated, Sponsor: Ocera Therapeutics
Recruiting --> Completed Active, not recruiting --> Terminated; Lack of enrollment
- Kremezin (AST-120) / Mitsubishi Tanabe
Enrollment change: Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis (clinicaltrials.gov) - May 20, 2013
P2, N=2, Terminated, Sponsor: Ocera Therapeutics
Active, not recruiting --> Terminated; Lack of enrollment N=20 --> 2
- | Kremezin (AST-120) / Mitsubishi Tanabe
New P4 trial: Effect of An Oral Absorbent AST-120 in Late-stage Chronic Kidney Disease (CKD) Patients. (clinicaltrials.gov) - Sep 5, 2012
P4, N=51, Completed, Sponsor: Chang Gung Memorial Hospital
- ||||||| Kremezin (AST-120) / Mitsubishi Tanabe
Trial completion, HEOR: A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2) (clinicaltrials.gov) - Nov 3, 2011
P3, N=1015, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
N=20 --> 2 Active, not recruiting --> Completed
- ||||||| Kremezin (AST-120) / Mitsubishi Tanabe
Trial completion: A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1) (clinicaltrials.gov) - Nov 3, 2011
P3, N=1020, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Kremezin (AST-120) / Mitsubishi Tanabe
New P4 trial: Effect of Replacement Volume of Haemodiafiltration and AST-120 on Toxins, Oxidative Stress and MicroInflammation (clinicaltrials.gov) - Oct 23, 2011
P4, N=30, Active, not recruiting, Sponsor: Tungs
- |||| Kremezin (AST-120) / Mitsubishi Tanabe
Trial completion: Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome (clinicaltrials.gov) - Sep 28, 2011
P2, N=100, Completed, Sponsor: Ocera Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Kremezin (AST-120) / Mitsubishi Tanabe
Trial completion: Safety and Efficacy of AST-120 in the Treatment of Pouchitis (clinicaltrials.gov) - Sep 28, 2011
P2, N=20, Completed, Sponsor: Ocera Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Kremezin (AST-120) / Mitsubishi Tanabe
Trial completion: AST015: Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy (clinicaltrials.gov) - Sep 28, 2011
P2, N=40, Completed, Sponsor: Ocera Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed